Clinical Trial Update: 5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy [NA]

View source ↗

Summary

This clinical trial update notes ongoing recruitment to evaluate 5-alpha reductase 2 as a biomarker of resistance to 5ARI therapy in prostatic conditions, inclu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Benign Prostatic Hyperplasia

Drugs mentioned

• DUTASTERIDE (Dutasteride)
• FINASTERIDE (FINASTERIDE)

Snippet

Sponsor: Beth Israel Deaconess Medical Center | Conditions: Benign Prostatic Hyperplasia, Prostate Hyperplasia | NA | Status: RECRUITING